Stopping testosterone for IVF: what FTM patients actually face
Quick answer
Taylor is a trans man who has been on testosterone for approximately three years, during which his menstrual cycle ceased within the first month. He describes a clinical protocol involving testosterone cessation, awaiting cycle resumption, ovarian stimulation with fertility medications, and egg retrieval before restarting testosterone, with a total estimated off-T window of four to five weeks. This aligns broadly with published reciprocal IVF protocols for trans men, though the two-week cycle resumption window he cites is optimistic and not universally achievable, particularly after extended testosterone use.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @shouldb3irish actually say?
Taylor, a trans man partnered with Madison, is preparing for reciprocal IVF at Mount Sinai in Toronto. He describes a timeline where he stops testosterone, waits up to two weeks for his cycle to return, then spends two to three weeks on fertility medications before a trigger shot and egg retrieval. His estimate: "about four to five weeks off of testosterone for this process." He also mentions stopping T completely before starting the fertility protocol, not tapering.
This is a firsthand account of a real clinical process, not a how-to guide. Taylor is clear he's sharing his specific situation and actively asks other trans men who've done this to share their experiences. That's a reasonable framing. He's not presenting himself as a medical authority, which matters when evaluating how literally viewers should take the timeline details.
Does the science back this up?
Mostly, yes, with some important caveats. The two-week window for menstrual resumption after stopping testosterone is plausible but not guaranteed for everyone. Research suggests it can take longer, and the timeline varies significantly based on duration of testosterone use and individual response.
A study by Grimstad et al. (2021, Fertility and Sterility) examined ovarian stimulation in transgender men and found that follicular development and hormonal response were comparable to cisgender women in most cases, though the path to getting there varied. The same study noted that menstrual resumption timing after testosterone cessation was not uniform. Mitu (2016, AMA Journal of Ethics) and more recent clinical guidance from the WPATH Standards of Care v8 (2022) both acknowledge that testosterone does not permanently eliminate ovarian function in most people, which supports Taylor's underlying premise that egg retrieval remains feasible.
The immediate restart of testosterone post-retrieval he mentions is consistent with clinical practice described in fertility literature for trans men, where the luteal phase window is short and resumption is generally considered safe once the procedure is complete.
What did they get wrong (or right)?
Taylor gets the broad strokes right. Testosterone does suppress but typically does not permanently destroy ovarian function. Cycles can return after cessation. Egg retrieval is possible. Restarting T after retrieval is standard practice. He deserves credit for accuracy on the basics.
Where the video falls short is the specificity of the two-week timeline. Taylor says "I have to go off testosterone for at least two weeks until my cycle comes back," framing it almost as a guarantee. That understates real variability. Moravek et al. (2020, Journal of Clinical Endocrinology and Metabolism) found that in some trans men, ovarian suppression from prolonged testosterone use meant delayed or incomplete response to gonadotropin stimulation, requiring protocol adjustments. Two weeks is the floor in some clinical protocols, not a reliable average.
He also says "nothing crazy will happen" in a month off T. That's subjective and dismissive of what dysphoria-related distress during cycle resumption can mean clinically. The mood and physical changes he says he's nervous about are documented in the literature, not minor inconveniences. Katz-Wise et al. (2018, International Journal of Sexual Health) found gender dysphoria symptoms frequently intensified during fertility treatment in trans men, particularly around menstruation resumption.
What should you actually know?
If you're a trans man considering egg freezing or reciprocal IVF, this video is a useful personal account but not a substitute for individualized medical guidance. The timeline Taylor describes reflects his specific protocol at one clinic. Yours may differ, sometimes significantly.
Key things the video does not address: not everyone will resume cycling within two weeks, particularly after longer testosterone use. Some protocols use exogenous hormonal priming to stimulate the ovaries without waiting for natural cycle resumption, which can shorten the off-T window. The WPATH Standards of Care v8 (2022) explicitly recommends that trans men considering future fertility discuss options before starting hormones, not as an afterthought.
Psychological support during the off-testosterone period is underrepresented in this video. The dysphoria that can accompany cycle return is real, documented, and worth discussing with a provider before stopping T, not just something to push through. If you are watching this and planning a similar process, talk to both a reproductive endocrinologist and a gender-affirming mental health provider in advance.
- Testosterone cessation timelines vary by individual and duration of use
- Ovarian stimulation in trans men is clinically feasible but not one-size-fits-all
- Psychological distress during the off-T period is common and worth proactive management
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Stopping testosterone for IVF: what FTM patients actually face, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Stopping testosterone for IVF: what FTM patients actually face is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Taylor is a trans man who has been on testosterone for approximately three years, during which his menstrual cycle ceased within the first month.
FormBlends verdict
Taylor is a trans man who has been on testosterone for approximately three years, during which his menstrual cycle ceased within the first month. He describes a clinical protocol involving testosterone cessation, awaiting cycle resumption, ovarian stimulation with fertility medications, and egg retrieval before restarting testosterone, with a total estimated off-T window of four to five weeks. This aligns broadly with published reciprocal IVF protocols for trans men, though the two-week cycle resumption window he cites is optimistic and not universally achievable, particularly after extended testosterone use.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Taylor is a trans man who has been on testosterone for approximately three years, during which his menstrual cycle ceased within the first month. He describes a clinical protocol involving testosterone cessation, awaiting cycle resumption, ovarian stimulation with fertility medications, and egg retrieval before restarting testosterone, with a total estimated off-T window of four to five weeks. This aligns broadly with published reciprocal IVF protocols for trans men, though the two-week cycle resumption window he cites is optimistic and not universally achievable, particularly after extended testosterone use.
- Testosterone-induced amenorrhea typically occurs within two to six months of starting T, per Hembree et al. (2017, Journal of Clinical Endocrinology and Metabolism), making Taylor's one-month experience faster than average but within the documented range.
- Ovarian function is not permanently eliminated by testosterone in most trans men. Grimstad et al. (2021, Fertility and Sterility) confirmed follicular development and hormonal response to stimulation were generally preserved.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Testosterone-induced amenorrhea typically occurs within two to six months of starting T, per Hembree et al. (2017, Journal of Clinical Endocrinology and Metabolism), making Taylor's one-month experience faster than average but within the documented range.
- Ovarian function is not permanently eliminated by testosterone in most trans men. Grimstad et al. (2021, Fertility and Sterility) confirmed follicular development and hormonal response to stimulation were generally preserved.
- The two-week cycle resumption window Taylor describes is a best-case estimate. After three or more years on testosterone, resumption can take longer and is not guaranteed within any fixed timeframe.
- Some fertility clinics use hormonal priming protocols that can reduce or eliminate the need to wait for natural cycle resumption, potentially shortening the off-T window compared to what Taylor describes.
- Psychological distress during the off-testosterone period is clinically documented and common. Katz-Wise et al. (2018, International Journal of Sexual Health) found gender dysphoria frequently intensified during fertility treatment in trans men, particularly around menstruation.
- WPATH Standards of Care v8 (2022) recommends trans individuals discuss fertility preservation options before initiating hormone therapy, not as a reactive decision during transition.
- Restarting testosterone immediately after egg retrieval is consistent with current clinical practice and does not appear to compromise fertility treatment outcomes based on available evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
TaterTot · TikTok creator
2.7K views on this video
Replying to @Mena Stopping testosterone! #ftm #ivf #mountsinai #fertility #hrt
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by TaterTot, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.